June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness
Author Affiliations & Notes
  • Seung Woo Lee
    Ophthalmology, Dongguk Unv, Gyeongju Hosp, Gyeongju
  • Jongyeop Park
    Ophthalmology, Dongguk Unv, Gyeongju Hosp, Gyeongju
  • Footnotes
    Commercial Relationships Seung Lee, None; Jongyeop Park, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3739. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seung Woo Lee, Jongyeop Park; Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3739.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness (SFCT) in patients with branch retinal vein occlusion.

Methods: This was an interventional, retrospective study of patients who were treated with intravitreal bevacizumab injection and had completed 12 months of follow-up. The study included 21 eyes (21 patients) in group 1 (1.25 mg bevacizumab) and 20 eyes (20 patients) in group 2 (2.5 mg bevacizumab). Complete ophthalmic examinations, fluorescein angiography, and enhanced depth imaging with spectral domain optical coherence tomography (SD-OCT) were performed at baseline and during follow-up.

Results: In group 1, SFCT changed from to 274.3 ± 99.2 μm at 3 months (P = 0.051), 277.2 ± 97.0 μm at 6 months(P = 0.043), 274.3 ± 99.2 μm at 9 months (P = 0.116) and 277.2 ± 97.0 μm at 12 months(P =0.086). In group 2, SFCT changed from to 294.8 ± 99.0 μm at 3 months (P = 0.048) , 293.8 ± 99.9 μm at 6 months(P = 0.064), 296.3 ± 97.3 μm at 9 months (P = 0.25) and 300.3 ± 102.2μm at 12 months(P =0.076). In group 1, the mean central macular thickness (CMT) decreased from 516.1 ± 157.4 µm at baseline to 288.6 ± 14.9 µm at 12 months (P < 0.05) and the average best-corrected visual acuity (BCVA) was 0.78 ± 0.54 and 0.20 ± 0.11 logMAR, respectively. In group 2, the mean CMT decreased from 508.7 ± 128.2 µm at baseline to 284.0 ± 29.8 µm at 12 months (P < 0.05) and the average BCVA was 0.57 ± 0.24 and 0.21 ± 0.11 logMAR, respectively. There were no significant differences in the final CMT or SFCT between the dose groups (P = 0.764 and P = 0.062, respectively).

Conclusions: SFCT decreased during the first 6 months after the initial bevacizumab injection, but was not significantly different at 12 months. In addition, the change in SFCT did not differ significantly according to the dose of intravitreal bevacizumab.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×